Observations with alpelisib in older patients (≥ 65 year of age) with breast cancer in a non-clinical trial setting
Author:
Funder
Betty J. Foust, M.D. and Parents' Professor of Oncology
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10549-021-06277-6.pdf
Reference6 articles.
1. André F, Ciruelos E, Rubovszky G, et al (2019) SOLAR-1 study group. alpelisib for pik3ca-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929–1940. https://doi.org/10.1056/NEJMoa1813904
2. O’Connor T, Shinde A, Doan C et al (2013) Managing breast cancer in the older patient. Clin Adv Hematol Oncol 11:341–347
3. Rugo HS, Andre F, Yamashita T et al (2020) Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol 31:P1001-1010
4. Ohno S, Mukai H, Narui K, Hozumi Y, Miyoshi Y, Yoshino H, Doihara H, Suto A, Tamura M, Morimoto T, Zaha H, Chishima T, Nishimura R, Ishikawa T, Uemura Y, Ohashi Y (2019) Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study. Breast Cancer Res Treat 176:631–635
5. Zaorsky NG, Zhang Y, Walter V, Tchelebi LT, Chinchilli VM, Gusani NJ (2019) Clinical trial accrual at initial course of therapy for cancer and its impact on survival. JNCCN J Natl Compr Cancer Netw 17:1309–1316
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Breast Cancer in the Elderly;Breast Cancer Updates;2023-05-03
2. Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience;Frontiers in Oncology;2022-10-20
3. Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects;Clinical Interventions in Aging;2022-09
4. Alpelisib;Reactions Weekly;2021-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3